Rocket Pharmaceuticals schedules November 5 results for Rocket Pharmaceuticals stock

Published on 10/20/2026 at 21:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cash stood at USD 283.70 million on June 30, 2026. Rocket Pharmaceuticals stock costs EUR 2.08 on October 20, 2026 at 9:47 p.m. CEST.

Reporting date November 5, 2026

Rocket Pharmaceuticals is scheduled to report results on November 5, 2026.
Cash, cash equivalents and investments totaled USD 283.70 million on June 30, 2026.
Rocket Pharmaceuticals stock costs EUR 2.08 at Lang & Schwarz on October 20, 2026 at 9:47 p.m. CEST.
Rocket Pharmaceuticals had a USD 255.20 million market capitalization on October 20, 2026.

RCKT, US77313F1066, Illustration mit AI erstellt.

Rocket Pharmaceuticals (ISIN US77313F1066) is scheduled to report its next results on November 5, 2026, according to Nasdaq. The date gives investors the next fixed checkpoint for a company whose pipeline remains centered on rare-disease gene therapies. Rocket Pharmaceuticals stock was trading at EUR 2.08 at Lang & Schwarz on October 20, 2026 at 9:47 p.m. CEST.

Cash runway remains central

Rocket Pharmaceuticals had cash, cash equivalents and investments of USD 283.70 million as of June 30, 2026. The company also received USD 35.00 million when it entered a Hercules Capital credit facility with borrowing capacity of up to USD 150.00 million on September 30, 2026, according to StockTitan. The filing said the resources and initial draw were expected to fund planned operations into the third quarter of 2028, subject to spending and financing conditions.

For the second quarter of 2026, Rocket reported an adjusted loss of USD 0.37 per share against a consensus loss of USD 0.24 per share, according to Sept Investing. The comparison shows that the upcoming report will be judged against a period in which the loss was wider than expected.

Stock stays near its yearly low

The latest structured quote placed RCKT at USD 2.33 on Nasdaq at 3:55 p.m. ET on October 20, 2026. Its USD 2.17 to USD 5.45 52-week range put the price USD 0.16 above the low and USD 3.12 below the high, while volume stood at 1,594,183 shares. Rocket Pharmaceuticals had a USD 255.20 million market capitalization at that time.

Valuation and upcoming date

Rocket Pharmaceuticals operates in biotechnology and develops genetic medicines for rare and life-threatening diseases. The company is listed on the Nasdaq Global Market under ticker RCKT, as stated in its filing. The November 5 reporting date is the next clearly identified corporate event in the current calendar.

Comparison with peers

Rocket Pharmaceuticals: USD 255.20 million market capitalization, price-to-earnings ratio minus 13.68. CRISPR Therapeutics (Nasdaq, USD): USD 4.83 billion market capitalization, price-to-earnings ratio minus 10.51. Beam Therapeutics (Nasdaq, USD): USD 2.58 billion market capitalization, price-to-earnings ratio minus 29.01.

What investors can measure next

The November report will put cash use, adjusted earnings and development spending beside the expected runway. The stock's wide USD 2.17 to USD 5.45 annual range also leaves clinical progress and financing terms as separate variables for valuation.

Rocket Pharmaceuticals stock was trading at EUR 2.08 at Lang & Schwarz on October 20, 2026 at 9:47 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Rocket Pharmaceuticals stock.